OrbiMed’s Tango Therapeutics TNGX Stock Holding History

OrbiMed’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-550,000	Closed	-$754K	–	120
2025 Q1	$754K	Hold	550,000	–	–	0.02%	103
2024 Q4	$1.7M	Buy	+550,000	New	+$2.55M	0.04%	105

Other funds holding TNGX

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

OrbiMed's TNGX Position: Q2 2025 in Review

OrbiMed sold out of Tango Therapeutics (TNGX) in Q2 2025, closing a stake of 550,000 shares — an estimated $754K sold.

OrbiMed first reported a position in TNGX in Q4 2024 and held it in 2 quarters. The position peaked at $1.7M in Q4 2024. 115 funds tracked by Wall St. Rank hold TNGX as of Q2 2025.

OrbiMed reported no remaining Tango Therapeutics position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 550,000 Tango Therapeutics shares in Q2 2025, an estimated $754K.
OrbiMed first reported a position in Tango Therapeutics in Q4 2024 and held it in 2 quarters.
OrbiMed's Tango Therapeutics position peaked at $1.7M in Q4 2024.
115 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.